Procept BioRobotics (PRCT) | Financial Analysis & Statements
Procept BioRobotics Corporation Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
76.4M
Gross Profit
46.3M
60.63%
Operating Income
-31.0M
-40.64%
Net Income
-29.8M
-39.07%
Balance Sheet Metrics
Total Assets
508.1M
Total Liabilities
142.2M
Shareholders Equity
365.9M
Debt to Equity
0.39
Cash Flow Metrics
Operating Cash Flow
-10.4M
Free Cash Flow
-12.2M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Procept BioRobotics Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 308.1M | 224.5M | 136.2M | 75.0M | 34.5M |
| Cost of Goods Sold | 111.8M | 87.4M | 65.1M | 37.9M | 18.6M |
| Gross Profit | 196.2M | 137.1M | 71.0M | 37.1M | 15.9M |
| Gross Margin % | 63.7% | 61.1% | 52.2% | 49.4% | 46.0% |
| Operating Expenses | |||||
| Research & Development | 71.3M | 62.3M | 48.4M | 29.0M | 19.0M |
| Selling, General & Administrative | 228.8M | 171.4M | 131.8M | 88.8M | 51.0M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 300.1M | 233.7M | 180.2M | 117.8M | 70.0M |
| Operating Income | -103.9M | -96.6M | -109.2M | -80.7M | -54.2M |
| Operating Margin % | -33.7% | -43.0% | -80.2% | -107.6% | -157.1% |
| Non-Operating Items | |||||
| Interest Income | 12.2M | 10.9M | 7.6M | 2.5M | 76.0K |
| Interest Expense | 3.6M | 4.2M | 4.0M | 5.2M | 5.8M |
| Other Non-Operating Income | -156.0K | -1.5M | -283.0K | -3.7M | 45.0K |
| Pre-tax Income | -95.4M | -91.4M | -105.9M | -87.2M | -59.9M |
| Income Tax | 190.0K | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -95.6M | -91.4M | -105.9M | -87.2M | -59.9M |
| Net Margin % | -31.0% | -40.7% | -77.8% | -116.2% | -173.6% |
| Key Metrics | |||||
| EBITDA | -85.4M | -81.9M | -98.0M | -75.6M | -50.9M |
| EPS (Basic) | $-1.72 | $-1.75 | $-2.24 | $-1.96 | $-3.63 |
| EPS (Diluted) | $-1.72 | $-1.75 | $-2.24 | $-1.96 | $-3.63 |
| Basic Shares Outstanding | 55544000 | 52125000 | 47255000 | 44400000 | 16480000 |
| Diluted Shares Outstanding | 55544000 | 52125000 | 47255000 | 44400000 | 16480000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Procept BioRobotics Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 286.5M | 333.7M | 257.2M | 221.9M | 304.3M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 83.5M | 83.5M | 48.4M | 15.3M | 4.5M |
| Inventory | 70.7M | 56.2M | 39.8M | 28.5M | 13.1M |
| Other Current Assets | 9.6M | 8.5M | 5.2M | 6.2M | 4.2M |
| Total Current Assets | 450.4M | 481.8M | 350.6M | 272.6M | 326.2M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 21.5M | 21.0M | 21.1M | 27.3M | 7.2M |
| Goodwill | 709.0K | 932.0K | 1.2M | 1.5M | 1.8M |
| Intangible Assets | 709.0K | 932.0K | 1.2M | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 9.1M | 5.6M | 4.0M | 3.1M | 777.0K |
| Total Non-Current Assets | 57.7M | 52.2M | 54.2M | 36.7M | 10.9M |
| Total Assets | 508.1M | 534.0M | 404.7M | 309.3M | 337.0M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 17.3M | 10.0M | 13.5M | 9.4M | 2.0M |
| Short-term Debt | 2.2M | 1.9M | 1.7M | 2.1M | 2.1M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 7.4M | 7.6M | 5.8M | 3.9M | 1.8M |
| Total Current Liabilities | 65.8M | 53.1M | 45.9M | 35.3M | 16.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | 76.3M | 78.3M | 77.5M | 75.2M | 52.0M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 147.0K | 324.0K | - | - | - |
| Total Non-Current Liabilities | 76.4M | 78.7M | 78.0M | 77.0M | 53.7M |
| Total Liabilities | 142.2M | 131.8M | 124.0M | 112.3M | 69.9M |
| Equity | |||||
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -641.6M | -546.0M | -454.6M | -348.7M | -261.5M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 365.9M | 402.2M | 280.8M | 197.1M | 267.1M |
| Key Metrics | |||||
| Total Debt | 78.5M | 80.2M | 79.2M | 77.3M | 54.1M |
| Working Capital | 384.6M | 428.7M | 304.6M | 237.3M | 309.9M |
Balance Sheet Composition
Procept BioRobotics Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -95.6M | -91.4M | -105.9M | -87.2M | -59.9M |
| Depreciation & Amortization | 6.4M | 5.2M | 3.8M | 2.8M | 3.3M |
| Stock-Based Compensation | 47.6M | 31.8M | 19.1M | 10.3M | 3.8M |
| Working Capital Changes | -8.5M | -48.9M | -30.8M | -17.3M | -5.0M |
| Operating Cash Flow | -50.6M | -103.6M | -113.7M | -89.8M | -58.0M |
| Investing Activities | |||||
| Capital Expenditures | -9.4M | -4.4M | -25.2M | -2.7M | -592.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -9.4M | -4.4M | -25.2M | -2.7M | -592.0K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | 0 | 0 | 51.2M | 0 |
| Debt Repayment | - | 0 | 0 | -50.0M | 0 |
| Financing Cash Flow | 0 | 164.5M | 161.7M | -2.8M | 257.1M |
| Free Cash Flow | -58.3M | -103.6M | -133.2M | -83.0M | -57.9M |
| Net Change in Cash | -59.9M | 56.5M | 22.8M | -95.3M | 198.4M |
Cash Flow Trend
Procept BioRobotics Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-14.09
Forward P/E
-28.38
Price to Book
3.86
Price to Sales
4.59
PEG Ratio
-0.27
Profitability Ratios
Profit Margin
-31.02%
Operating Margin
-40.64%
Return on Equity
-24.89%
Return on Assets
-12.46%
Financial Health
Current Ratio
6.84
Debt to Equity
21.45
Beta
0.93
Per Share Data
EPS (TTM)
$-1.72
Book Value per Share
$6.50
Revenue per Share
$5.55
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| PRCT | 1.4B | -14.09 | 3.86 | -24.89% | -31.02% | 21.45 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Stryker | 126.3B | 39.21 | 5.62 | 15.08% | 12.92% | 72.97 |
| Axogen | 1.9B | -110.18 | 13.15 | -13.49% | -6.97% | 55.50 |
| Establishment Labs | 1.9B | -37.89 | 79.68 | -133.25% | -24.19% | 1,123.15 |
| Artivion | 1.8B | 179.71 | 4.03 | 2.70% | 2.21% | 57.67 |
Financial data is updated regularly. All figures are in the company's reporting currency.






